126 related articles for article (PubMed ID: 37673586)
41. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
[TBL] [Abstract][Full Text] [Related]
42. Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma.
Muruganandan S; Alfonso H; Franklin P; Shilkin K; Segal A; Olsen N; Reid A; de Klerk N; Musk AB; Brims F
Br J Cancer; 2017 Mar; 116(6):703-708. PubMed ID: 28196068
[TBL] [Abstract][Full Text] [Related]
43. Pleural mesothelioma classification-update and challenges.
Dacic S
Mod Pathol; 2022 Jan; 35(Suppl 1):51-56. PubMed ID: 34465883
[TBL] [Abstract][Full Text] [Related]
44. Breast Cancer Molecular Subtype Prediction on Pathological Images with Discriminative Patch Selection and Multi-Instance Learning.
Liu H; Xu WD; Shang ZH; Wang XD; Zhou HY; Ma KW; Zhou H; Qi JL; Jiang JR; Tan LL; Zeng HM; Cai HJ; Wang KS; Qian YL
Front Oncol; 2022; 12():858453. PubMed ID: 35494021
[TBL] [Abstract][Full Text] [Related]
45. Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
Capkova L; Koubkova L; Kodet R
Neoplasma; 2014; 61(2):161-9. PubMed ID: 24471939
[TBL] [Abstract][Full Text] [Related]
46. Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.
Ascoli V; Minelli G; Cozzi I; Romeo E; Carnovale Scalzo C; Ancona L; Forastiere F
Pathol Res Pract; 2016 Oct; 212(10):886-892. PubMed ID: 27485167
[TBL] [Abstract][Full Text] [Related]
47. Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.
Marqués M; Tranchant R; Risa-Ebrí B; Suárez-Solís ML; Fernández LC; Carrillo-de-Santa-Pau E; Del Pozo N; Martínez de Villarreal J; Meiller C; Allory Y; Blum Y; Pirker C; Hegedus B; Barry ST; Carnero A; Berger W; Jean D; Real FX
Cancer Res; 2020 Feb; 80(4):843-856. PubMed ID: 31911549
[TBL] [Abstract][Full Text] [Related]
48. The Association between the Histological Subtypes of Mesothelioma and Asbestos Exposure Characteristics.
Vorster T; Mthombeni J; teWaterNaude J; Phillips JI
Int J Environ Res Public Health; 2022 Nov; 19(21):. PubMed ID: 36361401
[TBL] [Abstract][Full Text] [Related]
49. Reproducibility of Malignant Pleural Mesothelioma Histopathologic Subtyping.
Brcic L; Vlacic G; Quehenberger F; Kern I
Arch Pathol Lab Med; 2018 Jun; 142(6):747-752. PubMed ID: 29509030
[TBL] [Abstract][Full Text] [Related]
50. Graph Neural Network for representation learning of lung cancer.
Aftab R; Qiang Y; Zhao J; Urrehman Z; Zhao Z
BMC Cancer; 2023 Oct; 23(1):1037. PubMed ID: 37884929
[TBL] [Abstract][Full Text] [Related]
51. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.
Cigognetti M; Lonardi S; Fisogni S; Balzarini P; Pellegrini V; Tironi A; Bercich L; Bugatti M; Rossi G; Murer B; Barbareschi M; Giuliani S; Cavazza A; Marchetti G; Vermi W; Facchetti F
Mod Pathol; 2015 Aug; 28(8):1043-57. PubMed ID: 26022455
[TBL] [Abstract][Full Text] [Related]
52. Interobserver Agreement in Histopathological Subtyping of Malignant Pleural Mesotheliomas.
Mlika M; Mezni F
Turk Patoloji Derg; 2021; 37(1):56-62. PubMed ID: 32692400
[TBL] [Abstract][Full Text] [Related]
53. Malignant pleural mesothelioma showing rare morphology indistinguishable from myxofibrosarcoma concomitant with EGFR-mutated lung adenocarcinoma: A case report.
Onagi H; Hayashi T; Saito T; Kishikawa S; Takamochi K; Suzuki K
Int J Surg Case Rep; 2021 Aug; 85():106237. PubMed ID: 34333253
[TBL] [Abstract][Full Text] [Related]
54. ALPPL2 Is a Highly Specific and Targetable Tumor Cell Surface Antigen.
Su Y; Zhang X; Bidlingmaier S; Behrens CR; Lee NK; Liu B
Cancer Res; 2020 Oct; 80(20):4552-4564. PubMed ID: 32868383
[TBL] [Abstract][Full Text] [Related]
55. What's new in mesothelioma.
Ascoli V; Murer B; Nottegar A; Luchini C; Carella R; Calabrese F; Lunardi F; Cozzi I; Righi L
Pathologica; 2018 Mar; 110(1):12-28. PubMed ID: 30259910
[TBL] [Abstract][Full Text] [Related]
56. Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma.
Shinozaki-Ushiku A; Ushiku T; Morita S; Anraku M; Nakajima J; Fukayama M
Histopathology; 2017 Apr; 70(5):722-733. PubMed ID: 27859460
[TBL] [Abstract][Full Text] [Related]
57. Cross-scale multi-instance learning for pathological image diagnosis.
Deng R; Cui C; Remedios LW; Bao S; Womick RM; Chiron S; Li J; Roland JT; Lau KS; Liu Q; Wilson KT; Wang Y; Coburn LA; Landman BA; Huo Y
Med Image Anal; 2024 May; 94():103124. PubMed ID: 38428271
[TBL] [Abstract][Full Text] [Related]
58. Clinical and pathological observation of conversion therapy for malignant peritoneal mesothelioma: a case report and literature review.
Deng M; Zhang X; Xu C; Luo R; Chen L; Zhou Y; Hou Y
Pathol Oncol Res; 2023; 29():1611577. PubMed ID: 38273860
[No Abstract] [Full Text] [Related]
59. Deep multiple instance learning versus conventional deep single instance learning for interpretable oral cancer detection.
Koriakina N; Sladoje N; Bašić V; Lindblad J
PLoS One; 2024; 19(4):e0302169. PubMed ID: 38687694
[TBL] [Abstract][Full Text] [Related]
60. Biphasic Peritoneal Mesothelioma Is a Rare Tumor and a Diagnostic Challenge: A Case Report.
Subahi EA; Fadul A; Mohamed A; Alsayed A; Ali EA; Sayed S; Mustafa S; Wazwaz B; Fadul MH
Cureus; 2024 Jan; 16(1):e51725. PubMed ID: 38318560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
